Gilead Sciences (NASDAQ:GILD) Price Target Raised to $133.00

Gilead Sciences (NASDAQ:GILD) had its price target lifted by HSBC from $110.00 to $133.00 in a research report report published on Wednesday morning,MarketScreener reports. The brokerage currently has a hold rating on the biopharmaceutical company’s stock.

A number of other equities research analysts have also weighed in on the stock. Weiss Ratings reaffirmed a “buy (b)” rating on shares of Gilead Sciences in a report on Wednesday, October 8th. Daiwa Capital Markets upped their price objective on shares of Gilead Sciences from $128.00 to $129.00 and gave the company an “outperform” rating in a research report on Thursday, November 13th. JPMorgan Chase & Co. raised their target price on Gilead Sciences from $145.00 to $150.00 and gave the company an “overweight” rating in a research note on Friday, October 31st. Scotiabank initiated coverage on Gilead Sciences in a research report on Thursday, November 13th. They set a “sector outperform” rating and a $140.00 target price on the stock. Finally, Daiwa America upgraded Gilead Sciences from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, August 19th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $131.13.

Gilead Sciences Stock Performance

Shares of NASDAQ:GILD opened at $120.40 on Wednesday. The company has a market cap of $149.38 billion, a P/E ratio of 18.67, a PEG ratio of 0.68 and a beta of 0.32. The company has a debt-to-equity ratio of 1.03, a quick ratio of 1.31 and a current ratio of 1.45. Gilead Sciences has a one year low of $88.57 and a one year high of $128.70. The business’s 50-day simple moving average is $121.89 and its 200 day simple moving average is $115.71.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share for the quarter, topping analysts’ consensus estimates of $2.16 by $0.31. The firm had revenue of $7.77 billion during the quarter, compared to analysts’ expectations of $7.42 billion. Gilead Sciences had a return on equity of 51.86% and a net margin of 27.88%.Gilead Sciences’s quarterly revenue was up 3.0% compared to the same quarter last year. During the same quarter in the prior year, the business earned $2.02 EPS. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. On average, sell-side analysts forecast that Gilead Sciences will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 30th. Investors of record on Monday, December 15th will be paid a $0.79 dividend. This represents a $3.16 dividend on an annualized basis and a yield of 2.6%. The ex-dividend date is Monday, December 15th. Gilead Sciences’s dividend payout ratio (DPR) is 48.99%.

Insider Transactions at Gilead Sciences

In other Gilead Sciences news, CEO Daniel Patrick O’day sold 10,000 shares of the company’s stock in a transaction that occurred on Friday, November 28th. The stock was sold at an average price of $126.54, for a total transaction of $1,265,400.00. Following the sale, the chief executive officer owned 571,203 shares in the company, valued at $72,280,027.62. This represents a 1.72% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CFO Andrew D. Dickinson sold 2,500 shares of Gilead Sciences stock in a transaction that occurred on Monday, November 17th. The stock was sold at an average price of $125.23, for a total value of $313,075.00. Following the completion of the transaction, the chief financial officer owned 154,555 shares of the company’s stock, valued at approximately $19,354,922.65. The trade was a 1.59% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 135,757 shares of company stock valued at $16,616,127 over the last 90 days. Corporate insiders own 0.27% of the company’s stock.

Institutional Trading of Gilead Sciences

Institutional investors have recently added to or reduced their stakes in the business. Activest Wealth Management boosted its holdings in shares of Gilead Sciences by 2,837.5% in the 1st quarter. Activest Wealth Management now owns 235 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 227 shares during the period. GoalVest Advisory LLC lifted its holdings in Gilead Sciences by 7,566.7% in the second quarter. GoalVest Advisory LLC now owns 230 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 227 shares during the last quarter. Corundum Trust Company INC bought a new position in Gilead Sciences in the third quarter worth about $26,000. Harbor Asset Planning Inc. acquired a new position in Gilead Sciences in the second quarter valued at approximately $27,000. Finally, Putney Financial Group LLC grew its holdings in shares of Gilead Sciences by 53.4% during the second quarter. Putney Financial Group LLC now owns 270 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 94 shares during the last quarter. Institutional investors own 83.67% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.